| Malignant neoplasm of breast
Herceptin Hylecta vs Truqap
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Herceptin Hylecta vs Truqap with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTruqap has a higher rate of injection site reactions vs Herceptin Hylecta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Truqap but not Herceptin Hylecta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Herceptin Hylecta
Truqap
At A Glance
SC injection
Every 3 weeks
HER2 antagonist
Oral
Twice daily (4 days on, 3 days off)
AKT inhibitor
Indications
- Malignant neoplasm of breast
- Malignant neoplasm of breast
Dosing
Malignant neoplasm of breast 600 mg/10,000 units administered subcutaneously over approximately 2-5 minutes once every three weeks; no loading dose required; adjuvant patients treated for 52 weeks or until disease recurrence, metastatic patients treated until disease progression.
Malignant neoplasm of breast 400 mg orally twice daily (approximately 12 hours apart) with or without food, for 4 days followed by 3 days off, in combination with fulvestrant; continue until disease progression or unacceptable toxicity.
Contraindications
—
- Severe hypersensitivity to capivasertib or any of its components
Adverse Reactions
Most common (>=10%) Alopecia, nausea, administration-related reactions, neutropenia, diarrhea, asthenia, fatigue, vomiting, myalgia, decreased appetite, stomatitis, arthralgia, headache, rash, constipation, pyrexia, cough, anemia, dyspnea, peripheral sensory neuropathy, leukopenia, mucosal inflammation, hot flush, upper respiratory tract infection
Serious Neutropenia (Grade >=3), febrile neutropenia, leukopenia, left ventricular dysfunction, cardiomyopathy, pulmonary toxicity, hypersensitivity reactions
Postmarketing Administration-related reaction, oligohydramnios, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome
Most common (>=20%) Diarrhea, cutaneous adverse reactions, increased random glucose, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides, decreased neutrophils, increased creatinine, vomiting, stomatitis
Serious Cutaneous adverse reactions, diarrhea, pneumonia, vomiting, pyrexia, hyperglycemia, hypersensitivity, fatigue, renal injury, second malignancy
Pharmacology
Trastuzumab is a humanized IgG1 kappa monoclonal antibody that inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC); hyaluronidase reversibly increases subcutaneous tissue permeability by depolymerizing hyaluronan to enhance systemic absorption of trastuzumab.
Capivasertib is a pan-AKT inhibitor that blocks all three serine/threonine kinase AKT isoforms (AKT1, AKT2, AKT3), inhibiting phosphorylation of downstream AKT substrates and suppressing tumor growth driven by PIK3CA/AKT1/PTEN pathway alterations.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Herceptin Hylecta
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (0/12)
Truqap
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Herceptin Hylecta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Truqap
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Herceptin Hylecta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Truqap
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Bone Metastases
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Herceptin HylectaView full Herceptin Hylecta profile
TruqapView full Truqap profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.